Literature DB >> 29663482

Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions.

Iria Bravo1, Hortensia Álvarez2, Ana Mariño2, Bonaventura Clotet3,4,5,6,7, José Moltó3,4,5.   

Abstract

Entities:  

Keywords:  HIV infection; coronary disease; drug interactions

Mesh：

Substances：

Year:  2018        PMID： 29663482      PMCID： PMC6005598          DOI： 10.1111/bcp.13583

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  15 in total

1.  Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.

Authors:  Somjot S Brar; Jurrien ten Berg; Rossella Marcucci; Matthew J Price; Marco Valgimigli; Hyo-Soo Kim; Giuseppe Patti; Nicoline J Breet; Germano DiSciascio; Thomas Cuisset; George Dangas
Journal:  J Am Coll Cardiol       Date:  2011-11-01       Impact factor: 24.094

2.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

3.  Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions.

Authors:  Iria Bravo; Hortensia Álvarez; Ana Mariño; Bonaventura Clotet; José Moltó
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

Review 4.  Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy.

Authors:  Fabrizio D'Ascenzo; Enrico Cerrato; Giuseppe Biondi-Zoccai; Claudio Moretti; Pierluigi Omedè; Filippo Sciuto; Mario Bollati; Maria Grazia Modena; Fiorenzo Gaita; Imad Sheiban
Journal:  Eur Heart J       Date:  2011-12-20       Impact factor: 29.983

5.  Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting.

Authors:  Simon Schneider; Christoph D Spinner; Salvatore Cassese; Dominik Promny; Alexander Hapfelmeier; Robert A Byrne; Marcus Baumann; Hans Jäger; Eva Steinlechner; Karl-Ludwig Laugwitz; Adnan Kastrati
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

6.  Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

Authors:  N A Farid; C D Payne; D S Small; K J Winters; C S Ernest; J T Brandt; C Darstein; J A Jakubowski; D E Salazar
Journal:  Clin Pharmacol Ther       Date:  2007-03-14       Impact factor: 6.875

7.  Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.

Authors:  Marie Hauguel-Moreau; Franck Boccara; Anders Boyd; Joe-Elie Salem; Delphine Brugier; Angélique Curjol; Jean-Sébastien Hulot; Mathieu Kerneis; Sophie Galier; Ariel Cohen; Gilles Montalescot; Jean-Philippe Collet; Johanne Silvain
Journal:  Eur Heart J       Date:  2017-06-01       Impact factor: 29.983

Review 8.  Cardiovascular disease in HIV patients: from bench to bedside and backwards.

Authors:  Enrico Cerrato; Andrea Calcagno; Fabrizio D'Ascenzo; Giuseppe Biondi-Zoccai; Massimo Mancone; Walter Grosso Marra; Daniela Demarie; Pierluigi Omedè; Antonio Abbate; Stefano Bonora; James J DiNicolantonio; Vicente Estrada; Javier Escaned; Claudio Moretti; Fiorenzo Gaita
Journal:  Open Heart       Date:  2015-03-20

Review 9.  Acute coronary syndromes in patients with HIV.

Authors:  Valmiki K Seecheran; Stanley L Giddings; Naveen A Seecheran
Journal:  Coron Artery Dis       Date:  2017-03       Impact factor: 1.439

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971
View more
  8 in total

1.  Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions.

Authors:  Iria Bravo; Hortensia Álvarez; Ana Mariño; Bonaventura Clotet; José Moltó
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

Review 2.  A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

Authors:  Allison R Webel; Julie Schexnayder; Patricia A Cioe; Julie A Zuñiga
Journal:  J Assoc Nurses AIDS Care       Date:  2021 May-Jun 01       Impact factor: 1.809

Review 3.  The challenge of HIV treatment in an era of polypharmacy.

Authors:  David Back; Catia Marzolini
Journal:  J Int AIDS Soc       Date:  2020-02       Impact factor: 5.396

Review 4.  Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.

Authors:  Francesco Nappi; Adelaide Iervolino; Sanjeet Singh Avtaar Singh
Journal:  Biomedicines       Date:  2022-02-14

Review 5.  Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.

Authors:  Catia Marzolini; Daniel R Kuritzkes; Fiona Marra; Alison Boyle; Sara Gibbons; Charles Flexner; Anton Pozniak; Marta Boffito; Laura Waters; David Burger; David J Back; Saye Khoo
Journal:  Clin Pharmacol Ther       Date:  2022-05-14       Impact factor: 6.903

Review 6.  Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.

Authors:  Shubham Agarwal; Sanjeev Kumar Agarwal
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-12       Impact factor: 3.727

7.  Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO" Cohort.

Authors:  Emanuele Focà; Paola Magro; Giovanni Guaraldi; Agostino Riva; Anna Maria Cattelan; Giuseppe Vittorio De Socio; Cecilia Costa; Stefania Piconi; Benedetto Maurizio Celesia; Silvia Nozza; Giancarlo Orofino; Antonella Castagna; Giovanni Di Perri; Francesco Castelli; Andrea Calcagno
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

Review 8.  Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Authors:  Catherine Hodge; Fiona Marra; Catia Marzolini; Alison Boyle; Sara Gibbons; Marco Siccardi; David Burger; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.